Syndax Pharmaceuticals Inc (SNDX): Capital Expenditures
$187.0K
Year ended 2025-12-31
+14.3%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $187.0K | n/a | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $0 | n/a | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $0 | n/a | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $0 | -100.0% | 2024-02-27, From 2022-01-01 |
| 2021-12-31 | $129.0K | n/a | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $0 | n/a | 2023-02-28, From 2020-01-01 |
| No annual figure between 2018-12-31 and 2020-12-31. | |||
| 2018-12-31 | $187.0K | +122.6% | 2021-03-12, From 2018-01-01 |
| 2017-12-31 | $84.0K | -67.8% | 2020-03-05, From 2017-01-01 |
| 2016-12-31 | $261.0K | +432.7% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $49.0K | n/m | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $4.0K | n/a | 2017-03-14, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $187.0K | n/a |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $229.0K | +69.6% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $16.44M | -4.7% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $3.57M | +160.5% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $670.0K | +230.0% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $13.15M | -55.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $4.34M | -12.4% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $953.0K | n/a |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $317.0K | -81.4% |
Compare SNDX, PHAT, CYRX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗